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THE POTENTIAL BENEFITS AND DRAWBACKS 
OF ALLOWING DIRECT-TO-CONSUMER 
ADVERTISING OF PHARMACEUTICALS 
IN EUROPE
Dickson AJ
Consultant Health Economist, Northallerton, United Kingdom.
Whether to legalise direct-to-consumer advertising (DTCA),
the authorised advertising of prescription drugs direct to
the consumer, within the European Union (EU) is often
discussed. But how would allowing DTCA help EU gov-
ernments looking for solutions to rising costs, rising pa-
tient expectations, loss of public confidence and ageing
populations? This poster summarises the main arguments
for and against the EU legalising DTCA.
OBJECTIVES: To explore the arguments for and against
allowing the use of DTCA in EU states; to determine the
validity of the propounded arguments, by evaluating ac-
tual data which highlights the effects of introducing
DTCA in the US and New Zealand.
METHODS: Using PubMed and a within-literature
search, a literature review of published information on
the arguments for and against DTCA, and DTCA’s asso-
ciated costs was undertaken.
RESULTS: Advocates believe DTCA will enable the
pharmaceutical industry to significantly improve the ef-
fectiveness of its marketing campaigns. DTCA’s oppo-
nents argue that health-care provider’s ability to ration
health care based on clinical need will be destroyed. US
data indicates that DTCA rose 38.5% in 1999 to
$US1.8bn, whilst in New Zealand expenditure rose
47.1% in 2000 to $US21.5m. DTCA has caused US retail
spending on prescriptions to soar. Yet in New Zealand
DTCA is credited with improving awareness, choice and
treatment of previously neglected conditions.
CONCLUSIONS: DTCA’s ability to allow the pharma-
ceutical industry to connect with its ultimate consumers
(patients) would lead to increased strains on European
health systems. But, the increased awareness that DTCA
will bring to currently neglected conditions (such as os-
teoarthritis in men) could lead to huge benefits to patients
quality-of-lives and help refocus changing health systems
towards patients needs. As such, DTCA could be part of
the solution to Europe’s health care crisis, but its introduc-
tion will bring to EU states as many headaches as it solves.
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THE RELATIONSHIP BETWEEN NATIONAL 
HEALTH INSURANCE EXPENDITURE AND THE 
BURDEN OF DISEASE- AN EVIDENCE-BASED 
STUDY IN TAIWAN
Liang LY
National Yang-Ming University, Taipei, Taiwan
OBJECTIVE: To examine the relation between actual
National health insurance expenditure and the burden of
36 specific-disease with regression model.
METHODS: Claims data were obtained from the bureau
of National health insurance and the vital registration
data were from the department of health in Taiwan. We
compare disease-specific expenditure with the burden of
this disease. Thirty-six major diseases included cancers,
DM, heart and cerebrovascular disease, hypertension, re-
spiratory disease, musculoskeletal disorder, congenital
anomalies, and injury. The disease burden was measured
by DALYs, years of life lost, disease prevalence, number
of outpatients and outpatient visits, and number of inpa-
tients in January 1998. Regression analyses were con-
ducted with logarithmic transformation.
RESULTS: The total national health expenditure and
DALYs is US$8.231 billion, and 1,500,166 person-years,
respectively. DALYs were strongly associated with dis-
ease prevalence (r  0.73 p  .001) and number of inpa-
tients(r  0.87 p  .001). There was relation between the
amount of expenditure per number of patients (inpatients
and outpatients) and disease prevalence (r  0.62 p 
0.001). Multiple regression analysis identified prevalence
and DALYs as the main determinants of expenditure per
number of patients (R20.474 and 0.16 respectively) af-
ter adjusted variables in the model.
ARTHRITIS & OSTEOPOROSIS
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THERAPEUTIC COMPARABILITY OF
COX-2 INHIBITORS
Richter A, Sherrill E, von Scheele B, Devlin P
Research Triangle Institute-Health Solutions (RTI-HS), 
Research Triangle Park, NC, USA
OBJECTIVE: This evidence-based review evaluates the
therapeutic comparability of COX-2-specific inhibitor
drugs, celecoxib and rofecoxib, for use in arthritis.
METHODS: A literature search identified 28 random-
ized clinical trials comparing the two coxibs to placebo
and to non-selective NSAID controls. Evidence tables
were compiled for common outcomes and meta-analyses
conducted. Efficacy was assessed on three subscales
(pain, stiffness, and physical function), and safety was
analyzed using broad measures such as withdrawals due
to adverse events.
RESULTS: Both coxibs improve arthritis symptoms com-
pared to placebo. The evidence collected here does not
suggest an efficacy advantage for either drug over non-
selective NSAIDs. In osteoarthritis, small statistically sig-
nificant differences were detected between rofecoxib and
celecoxib when compared to their respective placebo
groups but not when compared to active controls. The
magnitude of the differences was below a level consid-
ered clinically important. In rheumatoid arthritis, both
coxibs in high doses demonstrate proof of efficacy com-
parable to non-selective NSAIDs. Rofecoxib had a higher
incidence of edema/hypertension. Celecoxib-treated pa-
tients suffered more dyspepsia/abdominal pain. Both
were shown to have reduced incidence of ulcers com-
